Results 151 to 160 of about 391,153 (267)

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Review I of the article by S. N. Bagaev, V. N. Zakharov, V. A. Orlov "Fundamental phenomena and laws in the structural and functional organization of the cardiovascular system"

Атеросклероз, 2011
B. F. Mordovin, S. E. Pekarsky
doaj  

Prognostic significance of circulating level of GRP78 in pulmonary arterial hypertension. [PDF]

BMC Cardiovasc Disord
Chen J, Chen W, Li Z, Luo J, Qiu H, Chen Y, Li J.   +6 more
europepmc   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

Balancing Risk and Hope: Insights Into Pregnancy Outcomes in Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
Segura de la Cal T, Pérez-Olivares C, Luna-López R, Martín de Miguel I, Cruz-Utrilla A, Villar O, Sarnago F, Muñoz P, Santiago Sánchez M, López Gude MJ, Velázquez M, Forcén L, Delgado JF, Arribas Ynsaurriaga F, Escribano-Subias P.   +14 more
europepmc   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
Byrd CE, Schramm JE, Yang J, Barnes AE, Griffiths M, Nichols WC, Ivy DD, Austin ED, Everett AD.   +8 more
europepmc   +1 more source

Lowering salivary pH with sugar‐containing gum augments salivary nitrite production and blood pressure reduction with dietary nitrate (beetroot juice)

British Journal of Clinical Pharmacology, EarlyView.
Acutely lowering salivary pH (with sugar‐containing acidic gum vs. sugar‐free gum) augments salivary nitrate reduction to nitrite, plasma nitrite concentration, and blood pressure lowering with dietary nitrate. Modifying salivary pH reveals a mechanism by which the nitrate‐nitrite‐NO pathway may be upregulated/inhibited, with potential for other ...
Andrew J. Webb, Harriet Clift, Callum Hill, Nur Mousa, Navanithan Arun Jayaraj, Jasmine Quraishi, Charlotte E. Mills, Kevin O'Gallagher   +7 more
wiley   +1 more source

Vascular compliance phenotyping in pulmonary arterial hypertension (a PVDOMICS study). [PDF]

JHLT Open
Wilson TG, Wilson TG, Oppegard L, Pi H, Houston BA, Tang WHW, Horn EM, Mukherjee M, Leary PJ, Robinson JC.   +9 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source